Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01743001 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT01743001 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 226 participants.
The verdict
NCT01743001, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
Interventions
- DRUG Placebo
- DRUG Macitentan 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2013-05-21 |
| Est. Completion | 2016-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01743001
The ClinicalTrials.gov registry entry for NCT01743001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01743001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01743001 about?
NCT01743001 is a clinical study titled "Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome". Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
What is the current status of trial NCT01743001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2013-05-21. Estimated completion is 2016-12-01.
What interventions are being tested in trial NCT01743001?
The interventions under investigation include: Placebo (DRUG), Macitentan 10 mg (DRUG).
Who is sponsoring clinical trial NCT01743001?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.